319.50

1.29% -4.58

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $319.50, with a volume of 38,227. It is down -1.29% in the last 24 hours and up +17.21% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$324.08

Open:

$322.82

24h Volume:

38,227

Relative Volume:

0.04

Market Cap:

$8.85B

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-34.84

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

+7.18%

1M Performance:

+17.21%

6M Performance:

+479.95%

1Y Performance:

+308.77%

1-Day Range:

$317.94

$326.83

1-Week Range:

$294.29

$326.91

52-Week Range:

$26.70

$326.91

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1119)

Industry

Biotechnology (627)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

10,998

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	319.00	8.99B	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	446.86	112.16B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.88	77.12B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	810.75	50.10B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	356.19	46.97B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	337.42	36.99B	4.98B	69.59M	525.67M	0.5197

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-25	Reiterated	Oppenheimer	Outperform
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Jan 19, 2026

Praxis speeds up R&D plans for seizure therapy after FDA feedback - MSN

Jan 19, 2026

Jan 17, 2026

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail

Jan 17, 2026

Praxis Precision Medicines stock hits 52-week high at $318.24 By Investing.com - Investing.com Nigeria

Jan 17, 2026

Jan 16, 2026

Praxis Precision Medicines (PRAX) Valuation As NDA Plans And New Clinical Leadership Point To Commercial Transition - Sahm

Jan 16, 2026

Praxis Precision Medicines stock hits 52-week high at $318.24 - Investing.com

Jan 16, 2026

PRAX Stock Price, Forecast & Analysis | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - Chartmill

Jan 16, 2026

Jan 15, 2026

Behavioral Patterns of PRAX and Institutional Flows - Stock Traders Daily

Jan 15, 2026

14 Best Booming Stocks to Buy Right Now - Insider Monkey

Jan 15, 2026